The influenza vaccines market has grown significantly over the recent past owing to the increasing disease prevalence and government initiatives to promote vaccination programs. Influenza, commonly known as flu, is an infectious respiratory illness caused by influenza viruses. Currently available influenza vaccines include the trivalent influenza vaccine (TIV) and quadrivalent influenza vaccine (QIV) which protect against three or four strains of the virus. These vaccines have made a significant positive impact by preventing millions of influenza illnesses every year.
The influenza vaccines market is estimated to be valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.
Advancements in recombinant vaccine technologies are Influenza Vaccines Market Demand Recombinant vaccines have several advantages over traditional egg-based vaccines such as consistent large-scale production, faster delivery, and capacity to handle pandemic strains. This is anticipated to increase their uptake in the coming years.
Key Takeaways
Key players operating in the influenza vaccines market include Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company.
Get More Insights On, Influenza Vaccines Market
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian